Literature DB >> 141241

[Therapy of recurrent herpes simplex and its surveillance by MIF determination: with levamisole, BCG, urushiol and herpes antigen vaccine (author's transl)].

R Jarisch, I Sandor.   

Abstract

Thirty patients with recurrent herpes simplex and 6 controls were included in our study. Before initiation of treatment, during therapy with Levamisole, BCG, poison ivy and herpes antigen vaccine and, thereafter, MIF-determinations were performed. The latter test proved to be a useful parameter in evaluating the sensitivity against herpes infection, (and subsequent recurrent manifestations), and effect of therapy. Treatment with Levamisole, BCG and herpes antigen vaccine was successful. MIF-inhibition values paralleled the therapeutic effect in the Levamisole- and herpes antigen vaccine treated group, not however, in the BCG-treated patients

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 141241     DOI: 10.1007/bf00561620

Source DB:  PubMed          Journal:  Arch Dermatol Res            Impact factor:   3.017


  11 in total

1.  Experimental immunosuppression induced by herpes simplex virus.

Authors:  R Cappel; C Henry; L Thiry
Journal:  Arch Virol       Date:  1975       Impact factor: 2.574

2.  Cellular immunity and circulating antibody to herpes simplex virus in subjects with recurrent herpex simplex lesions and controls as measured by the mixed leukocyte migration inhibition test and complement fixation.

Authors:  R W Gange; A de Bats; J R Park; C M Bradstreet; E L Rhodes
Journal:  Br J Dermatol       Date:  1975-11       Impact factor: 9.302

3.  Letter: Treatment of recurrent aphthous stomatitis and herpes with levamisole.

Authors:  J Symoens; J Brugmans
Journal:  Br Med J       Date:  1974-12-07

4.  [Interferon and interferon stimulation. New items in therapy of viral infections].

Authors:  D Fanta; J Söltz-Szötz
Journal:  Hautarzt       Date:  1974-07       Impact factor: 0.751

Review 5.  [Herpes simplex virus, type II: microbiology and clinical experiences with attenuated vaccine].

Authors:  T Nasemann; G Schaeg
Journal:  Hautarzt       Date:  1973-04       Impact factor: 0.751

6.  Poison oak hyposensitization. Evaluation of purified urushiol.

Authors:  W L Epstein; H Baer; C R Dawson; R G Khurana
Journal:  Arch Dermatol       Date:  1974-03

7.  In vitro parameters of cell-mediated immune reactions in healthy individuals following immune-stimulation attempts with levamisole.

Authors:  H Thulin; K Thestrup-Pedersen; J Ellegaard
Journal:  Acta Allergol       Date:  1975-04

8.  Cell-mediated immunity in Herpesvirus hominis infections.

Authors:  J M Wilton; L Ivanyi; T Lehner
Journal:  Br Med J       Date:  1972-03-18

9.  Immune specific production of interferon by human T cells in combined macrophage-lymphocyte cultures in response to Herpes simplex antigen.

Authors:  M J Valle; A M Bobrove; S Strober; T C Merigan
Journal:  J Immunol       Date:  1975-01       Impact factor: 5.422

10.  [Antibody titers--curse in patients with recurring Herpes simplex virus infections under vaccination with heat-inactivated Herpes viruses].

Authors:  W Remy; G Antoniadis; H Bockendahl; B Remy
Journal:  Z Hautkr       Date:  1976-02-01
View more
  4 in total

1.  Leukocyte migration inhibitory factor in primary and recurrent ocular infections by herpes simplex-virus.

Authors:  G Grabner; R Jarisch
Journal:  Albrecht Von Graefes Arch Klin Exp Ophthalmol       Date:  1979-07-02

2.  Vaccination for herpes simplex genitalis.

Authors:  T Nasemann; S W Wassilew
Journal:  Br J Vener Dis       Date:  1979-04

3.  [The leukocyte migration inhibition test (LMIT) in recurrent herpes simplex labialis. Comparison of the results of treatment with BCG and Levamisole (author's transl)].

Authors:  R Jarisch; I Sandor; C Cerni
Journal:  Arch Dermatol Res       Date:  1979-05-29       Impact factor: 3.017

4.  In vitro studies on the human cellular immune response to commercially available herpes simplex antigens.

Authors:  B M Czarnetzki; E Macher
Journal:  Arch Dermatol Res       Date:  1980       Impact factor: 3.017

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.